Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells

Open access
Lima-Fernandes, Evelyne, Murison, Alex, da Silva Medina, Tiago, Wang, Yadong, Ma, Anqi, Leung, Cherry, Luciani, Genna M., Haynes, Jennifer, Pollett, Aaron, Zeller, Constanze, Duan, Shili, Kreso, Antonija, Barsyte-Lovejoy, Dalia, Wouters, Bradly G., Jin, Jian, Carvalho, Daniel D. De, Lupien, Mathieu, Arrowsmith, Cheryl H., O’Brien, Catherine A. · 2019 · Nature Communications

Abstract

In embryonic stem cells, promoters of key lineage-specific differentiation genes are found in a bivalent state, having both activating H3K4me3 and repressive H3K27me3 histone marks, making them poised for transcription upon loss of H3K27me3. Whether cancer-initiating cells (C-ICs) have similar epigenetic mechanisms that prevent lineage commitment is unknown. Here we show that colorectal C-ICs (CC-ICs) are maintained in a stem-like state through a bivalent epigenetic mechanism. Disruption of the bivalent state through inhibition of the H3K27 methyltransferase EZH2, resulted in decreased self-renewal of patient-derived C-ICs. Epigenomic analyses revealed that the promoter of Indian Hedgehog (IHH), a canonical driver of normal colonocyte differentiation, exists in a bivalent chromatin state. Inhibition of EZH2 resulted in de-repression of IHH, decreased self-renewal, and increased sensitivity to chemotherapy in vivo. Our results reveal an epigenetic block to differentiation in CC-ICs and demonstrate the potential for epigenetic differentiation therapy of a solid tumour through EZH2 inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09309-4

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 EZH2 inhibition suppresses growth in patient-derived 3D colon cancer models. a Viable cell count of a patient-derived spheroidal culture, POP92, treated with chemical probes for the indicated epigenetic targets for 7 days. Data shown are mean calculated as percentage of DMSO control (n = 4, ± SEM, one-way ANOVA). b Epigenetic screen performed on six patient-derived organoid models. Data are represented as percentage of DMSO control. c Two patient-derived (POP92 and POP66) and one commercial cell line (LS174T) grown in spheroid CC-IC enriching cultures were treated with UNC1999 (left) and its negative control UNC2400 (right) for 7 days, and viable cell count was measured and normalised to control. Data shown are mean (n = 4, ± SD, two-way ANOVA). d Representative western blot showing the decrease of H3K27me3 and H3K27me2 levels in POP92 after 7 days of treatment with increasing concentrations of UNC1999. Quantification represents the percentage of H3K27me3 levels relative to those of total H3 determined and compared to DMSO control, (n = 4, ± SD, Student’s t test). e Proliferation of POP92 spheroids after EZH2 knockdown using two different shRNAs, or Luciferase shRNA control, monitored by Alamarblue. Data shown are mean (n = 4, ± SD, two-tailed t test). f Representative western blot showing the knockdown of EZH2 in the samples assessed for proliferation in (e). g EZH2 knockdown cells or shRNA luciferase control cells were treated with UNC1999 to show no further reduction in cell growth using viable cell count as readout. Data shown are mean (n = 3, ± SD, two-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file
Fig. 1 EZH2 inhibition suppresses growth in patient-derived 3D colon cancer models. a Viable cell count of a patient-derived spheroidal culture, POP92, treated with chemical probes for the indicated epigenetic targets for 7 days. Data shown are mean calculated as percentage of DMSO control (n = 4, ± SEM, one-way ANOVA). b Epigenetic screen performed on six patient-derived organoid models. Data are represented as percentage of DMSO control. c Two patient-derived (POP92 and POP66) and one commercial cell line (LS174T) grown in spheroid CC-IC enriching cultures were treated with UNC1999 (left) and its negative control UNC2400 (right) for 7 days, and viable cell count was measured and normalised to control. Data shown are mean (n = 4, ± SD, two-way ANOVA). d Representative western blot showing the decrease of H3K27me3 and H3K27me2 levels in POP92 after 7 days of treatment with increasing concentrations of UNC1999. Quantification represents the percentage of H3K27me3 levels relative to those of total H3 determined and compared to DMSO control, (n = 4, ± SD, Student’s t test). e Proliferation of POP92 spheroids after EZH2 knockdown using two different shRNAs, or Luciferase shRNA control, monitored by Alamarblue. Data shown are mean (n = 4, ± SD, two-tailed t test). f Representative western blot showing the knockdown of EZH2 in the samples assessed for proliferation in (e). g EZH2 knockdown cells or shRNA luciferase control cells were treated with UNC1999 to show no further reduction in cell growth using viable cell count as readout. Data shown are mean (n = 3, ± SD, two-way ANOVA). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 2 Inhibition of EZH2 reduces CC-IC frequency in vitro. a Tissue microarray samples processed for immunohistochemistry staining of EZH2 and H3K27me3. Pictures shown are representative of 32 patients (normal) and 251 patients (tumour). Scale bars are 200 µm (10 × ) and 50 µm (40 × ). b Intensity of IHC staining performed in (a) was scored manually as described in the Methods section, and plotted as median ± min and max, n = 32 (normal), n = 251 (tumour), Student’s t test. c Frequency of disease recurrence in patients within the top and bottom quintiles of EZH2 IHC expression as determined in (a, b) (EZH2-low IHC score < 2.4; EZH2-High IHC score > 9.6) (Chi-square test). d, e Pearson’s correlation value for EZH2 mRNA levels from TCGA CRC patient samples (COAD), compared with those of 257 genes from a colon crypt (stem cell) gene expression signature (d), and 388 genes from a colon top (differentiated) expression signature (e). Inverse correlations are plotted in red and positive correlations in blue. f TCF/LEF GFP Wnt reporter activity in POP92 and POP66 after 7 days of UNC1999 or UNC2400 treatment. Data are plotted normalised to DMSO control to the 10% brightest Wnt-High population (n = 4, ± SEM, two-way ANOVA). g–j Limiting dilution assay performed in vitro on UNC1999-pretreated cells at 3 µM for 7 days. Data shown are n = 4 (POP66, (h)), n = 6 (LS174T, (i)), n = 6 (POP92, (j)). Data are shown as mean ± 95% confidence interval, frequency and probability were computed using ELDA software) *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file
Fig. 2 Inhibition of EZH2 reduces CC-IC frequency in vitro. a Tissue microarray samples processed for immunohistochemistry staining of EZH2 and H3K27me3. Pictures shown are representative of 32 patients (normal) and 251 patients (tumour). Scale bars are 200 µm (10 × ) and 50 µm (40 × ). b Intensity of IHC staining performed in (a) was scored manually as described in the Methods section, and plotted as median ± min and max, n = 32 (normal), n = 251 (tumour), Student’s t test. c Frequency of disease recurrence in patients within the top and bottom quintiles of EZH2 IHC expression as determined in (a, b) (EZH2-low IHC score < 2.4; EZH2-High IHC score > 9.6) (Chi-square test). d, e Pearson’s correlation value for EZH2 mRNA levels from TCGA CRC patient samples (COAD), compared with those of 257 genes from a colon crypt (stem cell) gene expression signature (d), and 388 genes from a colon top (differentiated) expression signature (e). Inverse correlations are plotted in red and positive correlations in blue. f TCF/LEF GFP Wnt reporter activity in POP92 and POP66 after 7 days of UNC1999 or UNC2400 treatment. Data are plotted normalised to DMSO control to the 10% brightest Wnt-High population (n = 4, ± SEM, two-way ANOVA). g–j Limiting dilution assay performed in vitro on UNC1999-pretreated cells at 3 µM for 7 days. Data shown are n = 4 (POP66, (h)), n = 6 (LS174T, (i)), n = 6 (POP92, (j)). Data are shown as mean ± 95% confidence interval, frequency and probability were computed using ELDA software) *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 3 Inhibition of EZH2 reduces tumour growth and CC-IC frequency in vivo. a Dosing schedule for UNC1999 in vivo. Mice are dosed for 11-day cycles of 9 continuous days followed by a 2-day break. b, c Tumour volume measurements of POP92 and POP66. Mice were treated with vehicle or UNC1999 at 300 mg per kg of body weight for 20 days (b) or 25 days (c). Data shown are n = 37 tumours (b, vehicle), n = 42 (b, UNC1999), n = 20 (c, vehicle) or n = 30 (c, UNC1999) ± SEM, with two-way ANOVA. d Images of tumours from POP92 collected in (b). e Tumour weight measurement from xenografts collected in (b, c). Data are mean of n = 37 tumours (POP92 vehicle), n = 42 (POP92 UNC1999), n = 20 (POP66 vehicle) or n = 30 (POP66 UNC1999), ± SEM, Student's t test. f Representative western blots showing the reduction of H3K27me3 in the xenografts collected from POP92 and POP66 samples in (b, c) respectively. g Quantification of the western blots in (f) for H3K27me3 signal over total H3 normalised to the vehicle control. Data shown are n = 5 tumours ± SEM with two-tailed Student’s t test. h Schematic of the serial in vivo limiting dilution assay performed in (i, j). The first passage LDA was performed using POP92 tumours collected in (b). Mice were treated for 20 days with UNC1999 at 300 mg/kg, tumours were collected, prepared as single cells and serially diluted and reinjected into primary recipient mice without further treatments (i). The second passage LDA (j) was performed upon growth of tumours in (i): samples were collected, prepared as single cells and reinjected into secondary recipient mice without further treatments (j). Data in (i, j) are shown as mean ± 95% confidence interval, frequency and probability were computed using ELDA software. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file
Fig. 3 Inhibition of EZH2 reduces tumour growth and CC-IC frequency in vivo. a Dosing schedule for UNC1999 in vivo. Mice are dosed for 11-day cycles of 9 continuous days followed by a 2-day break. b, c Tumour volume measurements of POP92 and POP66. Mice were treated with vehicle or UNC1999 at 300 mg per kg of body weight for 20 days (b) or 25 days (c). Data shown are n = 37 tumours (b, vehicle), n = 42 (b, UNC1999), n = 20 (c, vehicle) or n = 30 (c, UNC1999) ± SEM, with two-way ANOVA. d Images of tumours from POP92 collected in (b). e Tumour weight measurement from xenografts collected in (b, c). Data are mean of n = 37 tumours (POP92 vehicle), n = 42 (POP92 UNC1999), n = 20 (POP66 vehicle) or n = 30 (POP66 UNC1999), ± SEM, Student's t test. f Representative western blots showing the reduction of H3K27me3 in the xenografts collected from POP92 and POP66 samples in (b, c) respectively. g Quantification of the western blots in (f) for H3K27me3 signal over total H3 normalised to the vehicle control. Data shown are n = 5 tumours ± SEM with two-tailed Student’s t test. h Schematic of the serial in vivo limiting dilution assay performed in (i, j). The first passage LDA was performed using POP92 tumours collected in (b). Mice were treated for 20 days with UNC1999 at 300 mg/kg, tumours were collected, prepared as single cells and serially diluted and reinjected into primary recipient mice without further treatments (i). The second passage LDA (j) was performed upon growth of tumours in (i): samples were collected, prepared as single cells and reinjected into secondary recipient mice without further treatments (j). Data in (i, j) are shown as mean ± 95% confidence interval, frequency and probability were computed using ELDA software. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 4 EZH2 Inhibition de-represses the colonic differentiation gene IHH. a RNA-seq heatmap of log2 fold change for all genes significantly upregulated (red in top panel) or downregulated (blue in bottom panel) following UNC1999 treatment in POP92 cells. Lower bars underneath the heatmap indicate ChIP-seq data for POP92 cells in the absence of UNC1999. The presence of H3K4me3 peaks (green), H3K27me3 peaks (pink) or regions where both marks directly overlap (Bivalent; purple) in promoter regions (2.5 kb upstream of TSS, 0.5 kb downstream of TSS) is shown (prior to UNC199 treatment) for all genes whose expression is significantly changed after UNC1999 treatment (negative binomial, FDR-corrected q < 0.05). RNA-Seq was performed in (n = 3) biological replicates for each condition, ChIP-seq peaks called in n = 2 separate replicates were used for each mark. b GSEA performed on the differentially regulated transcripts from RNA-seq data with respect to the Colon Crypt signature (FWER, p < 0.03). c GSEA performed on 30 randomly selected sets of 200 genes with H3K4me3 (green), H3K27me3 (pink), mixed (blue) or bivalent (purple) marks in their promoters. Distribution of normalised enrichment scores are shown along with the percentage of runs which were significantly enriched among upregulated genes following UNC1999 treatment (p < 0.25, none were significant among downregulated genes). d Enriched biological process GO terms within all genes differentially upregulated following UNC1999 treatment with H3K27me3 marks in their promoter. Matrix shows which differentially expressed genes are present in each GO category, barplot shows −log2 FDR-corrected q-value. Genes with bivalently marked promoters are highlighted in purple. e Boxplot of differential expression of IHH following UNC1999 treatment (mean of n = 3), error bars show max and min estimated FPKM values, Student’s t test. f Representative ChIP-Seq tracks for H3K27me3 and H3K4me3 showing read counts over the IHH locus inclusive of the promoter region. g Transcription factor motif analyses performed on the predicted CREs (defined using ATAC-Seq) of UNC1999-differentially upregulated genes using homer, relative to a background of all ATAC-Seq peaks. **P < 0.01
Fig. 4 EZH2 Inhibition de-represses the colonic differentiation gene IHH. a RNA-seq heatmap of log2 fold change for all genes significantly upregulated (red in top panel) or downregulated (blue in bottom panel) following UNC1999 treatment in POP92 cells. Lower bars underneath the heatmap indicate ChIP-seq data for POP92 cells in the absence of UNC1999. The presence of H3K4me3 peaks (green), H3K27me3 peaks (pink) or regions where both marks directly overlap (Bivalent; purple) in promoter regions (2.5 kb upstream of TSS, 0.5 kb downstream of TSS) is shown (prior to UNC199 treatment) for all genes whose expression is significantly changed after UNC1999 treatment (negative binomial, FDR-corrected q < 0.05). RNA-Seq was performed in (n = 3) biological replicates for each condition, ChIP-seq peaks called in n = 2 separate replicates were used for each mark. b GSEA performed on the differentially regulated transcripts from RNA-seq data with respect to the Colon Crypt signature (FWER, p < 0.03). c GSEA performed on 30 randomly selected sets of 200 genes with H3K4me3 (green), H3K27me3 (pink), mixed (blue) or bivalent (purple) marks in their promoters. Distribution of normalised enrichment scores are shown along with the percentage of runs which were significantly enriched among upregulated genes following UNC1999 treatment (p < 0.25, none were significant among downregulated genes). d Enriched biological process GO terms within all genes differentially upregulated following UNC1999 treatment with H3K27me3 marks in their promoter. Matrix shows which differentially expressed genes are present in each GO category, barplot shows −log2 FDR-corrected q-value. Genes with bivalently marked promoters are highlighted in purple. e Boxplot of differential expression of IHH following UNC1999 treatment (mean of n = 3), error bars show max and min estimated FPKM values, Student’s t test. f Representative ChIP-Seq tracks for H3K27me3 and H3K4me3 showing read counts over the IHH locus inclusive of the promoter region. g Transcription factor motif analyses performed on the predicted CREs (defined using ATAC-Seq) of UNC1999-differentially upregulated genes using homer, relative to a background of all ATAC-Seq peaks. **P < 0.01CC BY · PubMed Central
Fig. 5 EZH2 regulates CC-IC self-renewal through control of IHH expression. a RT-qPCR for IHH of UNC1999-treated cells. Cells were treated with UNC1999 at 3 µM for 7 days and processed for RT-qPCR. Data shown are mean (POP66/POP92 n = 6, LS174T n = 4, ± SD, Student’s t test). b–d mRNA Levels on POP92 CC-ICs of Hedgehog target genes Gli1 and BMP4 (b), differentiation markers FABP2 and CDX2 (c), and the stem cell markers OCT4, KLF4, NANOG (d) monitored by RT-qPCR following UNC1999 or UNC2400 treatment (3 µM), or recombinant IHH (5 µg/mL) for 7 days. Data shown are mean (n = 4, ± SEM, one-way ANOVA). e LDA on POP92, POP66 and LS174T cells pretreated with recombinant IHH (5 µg/mL) for 10 days. Data shown are n = 3 and represent mean ± 95% confidence interval, frequency and probability were computed using ELDA software. f POP92 spheroids treated with DMSO or UNC1999 (3 µM) in the presence of SMO inhibitor Vismodegib (10 µM) or DMSO control for 7 days. Viable cell count was measured and samples normalised to their respective control. Data shown are mean (n = 5, ± SD, two-way ANOVA). g IHH knocked down in POP92 using two different hairpins, and sensitivity towards UNC1999 was assessed using viable cell count via flow cytometry. Data are normalised to DMSO control performed in n = 3, ± SD, two-way ANOVA. h POP92 with IHH knockdown were treated with UNC1999 (3 μM) or DMSO control for 7 days prior to seeding in LDA. Data shown are n = 2 and represented as mean ± 95% confidence interval. Frequency and statistics were computed using ELDA software. i POP92 spheroids infected with either shRNA against Luciferase (shLuc) or shRNA targeting IHH (shIHH) were injected into mice and treated with vehicle or UNC1999 (300 mg/kg). Tumour volume was measured over time. Data are n = 20 tumours (shLuc ± UNC1999), n = 19 tumours (shIHH ± UNC1999), ± SEM, two-way ANOVA with Tukey multiple test correction. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file
Fig. 5 EZH2 regulates CC-IC self-renewal through control of IHH expression. a RT-qPCR for IHH of UNC1999-treated cells. Cells were treated with UNC1999 at 3 µM for 7 days and processed for RT-qPCR. Data shown are mean (POP66/POP92 n = 6, LS174T n = 4, ± SD, Student’s t test). b–d mRNA Levels on POP92 CC-ICs of Hedgehog target genes Gli1 and BMP4 (b), differentiation markers FABP2 and CDX2 (c), and the stem cell markers OCT4, KLF4, NANOG (d) monitored by RT-qPCR following UNC1999 or UNC2400 treatment (3 µM), or recombinant IHH (5 µg/mL) for 7 days. Data shown are mean (n = 4, ± SEM, one-way ANOVA). e LDA on POP92, POP66 and LS174T cells pretreated with recombinant IHH (5 µg/mL) for 10 days. Data shown are n = 3 and represent mean ± 95% confidence interval, frequency and probability were computed using ELDA software. f POP92 spheroids treated with DMSO or UNC1999 (3 µM) in the presence of SMO inhibitor Vismodegib (10 µM) or DMSO control for 7 days. Viable cell count was measured and samples normalised to their respective control. Data shown are mean (n = 5, ± SD, two-way ANOVA). g IHH knocked down in POP92 using two different hairpins, and sensitivity towards UNC1999 was assessed using viable cell count via flow cytometry. Data are normalised to DMSO control performed in n = 3, ± SD, two-way ANOVA. h POP92 with IHH knockdown were treated with UNC1999 (3 μM) or DMSO control for 7 days prior to seeding in LDA. Data shown are n = 2 and represented as mean ± 95% confidence interval. Frequency and statistics were computed using ELDA software. i POP92 spheroids infected with either shRNA against Luciferase (shLuc) or shRNA targeting IHH (shIHH) were injected into mice and treated with vehicle or UNC1999 (300 mg/kg). Tumour volume was measured over time. Data are n = 20 tumours (shLuc ± UNC1999), n = 19 tumours (shIHH ± UNC1999), ± SEM, two-way ANOVA with Tukey multiple test correction. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data fileCC BY · PubMed Central
Fig. 6 UNC1999 treatment in vivo increases chemosensitivity to 5-Fluorouracil. a POP92 in vitro combination of UNC1999 (3 µM) and increasing doses of 5-FU. Cells were pretreated with UNC1999 (3 µM) for 3 days, after which 5-FU was added and cells incubated for 4 additional days. Viable cell count was measured and samples normalised to their respective control. Data shown are mean (n = 4, ±SEM, two-way ANOVA). Table shows shift in 5-FU IC50 in UNC1999-pretreated cells. b Sequential treatment of UNC1999 (300 mg/kg, oral gavage) and 5-FU (15 mg/kg, IP). Mice were dosed with either vehicle, UNC1999 alone, 5-FU alone, or 5-FU and UNC1999 in combination (Combo): 10-day cycles starting with UNC1999 for 5 days, followed by 5-FU every other day for 5 days. c Tumour size was measured over time. Data represent mean ± SEM of n = 13 tumours (vehicle), n = 12 (5-FU), n = 22 (UNC1999) or n = 15 (combo), two-way ANOVA compared to vehicle alone. d Xenografts collected from the mice treated in (c). e Tumour weight measurements of the xenografts collected in (c) and shown in (d). Data represent mean ± SEM of n = 13 tumours (vehicle), n = 12 (5-FU), n = 22 (UNC1999) or n = 15 (combo), one-way ANOVA. f Quantification of the reduction in H3K27me3 by western blot. Data shown are n = 7 tumours ± SEM, one-way ANOVA. g In vivo LDA performed with xenografts collected in (c). Data shown are represented as mean ± 95% confidence interval. Frequency and statistics were computed using ELDA software. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file
Fig. 6 UNC1999 treatment in vivo increases chemosensitivity to 5-Fluorouracil. a POP92 in vitro combination of UNC1999 (3 µM) and increasing doses of 5-FU. Cells were pretreated with UNC1999 (3 µM) for 3 days, after which 5-FU was added and cells incubated for 4 additional days. Viable cell count was measured and samples normalised to their respective control. Data shown are mean (n = 4, ±SEM, two-way ANOVA). Table shows shift in 5-FU IC50 in UNC1999-pretreated cells. b Sequential treatment of UNC1999 (300 mg/kg, oral gavage) and 5-FU (15 mg/kg, IP). Mice were dosed with either vehicle, UNC1999 alone, 5-FU alone, or 5-FU and UNC1999 in combination (Combo): 10-day cycles starting with UNC1999 for 5 days, followed by 5-FU every other day for 5 days. c Tumour size was measured over time. Data represent mean ± SEM of n = 13 tumours (vehicle), n = 12 (5-FU), n = 22 (UNC1999) or n = 15 (combo), two-way ANOVA compared to vehicle alone. d Xenografts collected from the mice treated in (c). e Tumour weight measurements of the xenografts collected in (c) and shown in (d). Data represent mean ± SEM of n = 13 tumours (vehicle), n = 12 (5-FU), n = 22 (UNC1999) or n = 15 (combo), one-way ANOVA. f Quantification of the reduction in H3K27me3 by western blot. Data shown are n = 7 tumours ± SEM, one-way ANOVA. g In vivo LDA performed with xenografts collected in (c). Data shown are represented as mean ± 95% confidence interval. Frequency and statistics were computed using ELDA software. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data fileCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 50

Metadata

Authors
Lima-Fernandes, E., Murison, A., da Silva Medina, T., Wang, Y., Ma, A., Leung, C., Luciani, G. M., Haynes, J., Pollett, A., Zeller, C., Duan, S., Kreso, A., Barsyte-Lovejoy, D., Wouters, B. G., Jin, J., Carvalho, D. D. D., Lupien, M., Arrowsmith, C. H., & O’Brien, C. A.
Affiliations
  • University Health Network (CA)
  • Tisch Cancer Institute (US)
  • University of Toronto (CA)
  • Ontario Institute for Cancer Research (CA)
Corresponding author
Arrowsmith, Cheryl H.
Venue
Nature Communications
Published
2019-03-29
Volume
10
Issue
1
Pages
1436-1436
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2926277490
Cited by
50
References
63
Citations by year
2026: 4 · 2025: 7 · 2024: 4 · 2023: 7 · 2022: 8 · 2021: 11 · 2020: 9
FWCI
2.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Pfizer
  • Genome Canada (115766, 1097737, OGI-055)
  • Merck KGaA
  • Wellcome Trust (1097737)
  • Ontario Genomics
  • European Federation of Pharmaceutical Industries and Associations (115766)
  • Ontario Genomics Institute (OGI-055, 115766)
  • European Commission (1097737, FP7‐COFUND, 115766)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (1097737, 115766)
  • Fonds National de la Recherche Luxembourg (FP7-COFUND)
  • Ontario Ministry of Research, Innovation and Science
  • National Institutes of Health (115766, 1097737)
  • Novartis Pharma
  • Canadian Institutes of Health Research (1097737)
  • National Cancer Institute (R01CA230854, R01CA218600)
  • National Institute of General Medical Sciences (R01GM122749)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD088626)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
bivalent chromatin, Indian hedgehog, EZH2, self-renewal, H3K27me3, H3K4me3, epigenetic reprogramming, differentiation therapy, chemosensitivity, histone methyltransferase inhibition
MeSH terms
Cell Self Renewal, Enhancer of Zeste Homolog 2 Protein, Animals, Benzamides, Cell Differentiation, Female, Fluorouracil, Humans, Indazoles, Male, Piperazines, Pyridones, Neoplastic Stem Cells, Colorectal Neoplasms, Mice, SCID, Mice, Inbred NOD, Cell Proliferation, Hedgehog Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. https://app.cochat.ai/papers/10.1038/s41467-019-09309-4
The paper
Lima-Fernandes, E., Murison, A., da Silva Medina, T., Wang, Y., Ma, A., Leung, C., Luciani, G. M., Haynes, J., Pollett, A., Zeller, C., Duan, S., Kreso, A., Barsyte-Lovejoy, D., Wouters, B. G., Jin, J., Carvalho, D. D. D., Lupien, M., Arrowsmith, C. H., & O’Brien, C. A. (2019). Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. Nature Communications. https://doi.org/10.1038/s41467-019-09309-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.